Systemic Immune Activation and Peripheral Blood Lymphocytes during Primary Chemotherapy with the Combination of Doxorubicin and Paclitaxel in Patients with Breast Carcinoma
Melichar Bohuslav,
Touskova Miroslava,
Hornychova Helena,
Vokurkova Doris,
Solichova Dagmar,
Vesely Pavel,
Mergancova Jindriska,
Urminska Hana,
Ryska Ales
Affiliations
Melichar Bohuslav
Klinika onkologie a radioterapie, Lekarska fakulta Univerzity Karlovy a Fakultni nemocnice, Budova 23, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. Tel +420-49-5834574; fax +420-49-583208
Touskova Miroslava
Departments of Immunology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Hornychova Helena
Departments of Pathology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Vokurkova Doris
Departments of Immunology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Solichova Dagmar
Departments of Gerontology & Metabolic Care, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Vesely Pavel
Departments of Oncology and Radiotherapy, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Mergancova Jindriska
Departments of Surgery, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Urminska Hana
Departments of Radiology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
Ryska Ales
Departments of Pathology, Charles University Medical School & Teaching Hospital, Hradec Kralove, Czech Republic
In recent years, there has been interest in the study of alterations of the immune system of breast carcinoma patients undergoing primary chemotherapy. Changes in the phenotype, function of peripheral blood lymphocytes as well as alterations in the release of pro-inflammatory cytokines accompanying the administration of primary chemotherapy have been described. We have investigated urinary neopterin and peripheral blood leukocyte phenotype in 44 breast carcinoma patients treated with the combination of doxorubicin and paclitaxel.